| Previous Close | 1.59 |
| Open | 1.59 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 1.57 - 1.67 |
| 52 Week Range | 1.20 - 8.22 |
| Volume | 921,777 |
| Avg. Volume | 848,510 |
| Market Cap | 121.88M |
| Beta | 1.12 |
| PE Ratio (TTM) | -1.84 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Capital Cube•last month
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : May 26, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Arrowhead Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ARWR-US. Comparing the performance and risk of Arrowhead Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ARWR earnings conference call or presentation 3-May-17 8:30pm GMT
Q2 2017 Arrowhead Pharmaceuticals Inc Earnings Call
- Capital Cube•2 months ago
Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017
Categories: Yahoo FinanceGet free summary analysis Arrowhead Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Arrowhead Pharmaceuticals, Inc. – Shire PLC Sponsored ADR, Johnson & Johnson and Nanophase Technologies Corporation (SHPG-US, JNJ-US and NANX-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)
